{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-399416","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2026-09-23T20:13:57+00:00","discovered_at":"2026-09-23T20:15:02.398273+00:00","generated_at":"2026-09-23T20:15:23.597224+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sarepta settles patent litigations with REGENXBIO and UPenn for $39M","bullets":["Sarepta to pay REGENXBIO $39.0M lump sum within 10 days to settle patent disputes over AAVrh74 capsid and ELEVIDYS.","Settlement resolves infringement claims involving U.S. Patents 11,680,274 and 10,526,617; releases Sarepta and Catalent from past claims.","Parties agree to dismiss pending litigations with prejudice; no admission of liability; each bears own costs.","Company had recorded $39.0M litigation contingency charge in Q2 2026 related to anticipated settlement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-399416","json":"https://secwatch.observer/filing/0001193125-26-399416.json","markdown":"https://secwatch.observer/filing/0001193125-26-399416.md","text":"https://secwatch.observer/filing/0001193125-26-399416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/0001193125-26-399416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/srpt-20260923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:15:23.597224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}